Nerve growth factor (NGF)
Assets acting on this target.
- Class
- Anti-NGF monoclonal antibody
- Notes
- mechanism wave 2026-08-24 (DeepSeek draft; registry text of NCT04163419 names the target); source: https://clinicaltrials.gov/study/NCT04163419
Assets acting on this target.
2 of 2 assets (2 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| JNJ-42160443 | Johnson & Johnson | Nerve growth factor (NGF) | Diabetic Peripheral Neuropathic Pain | Ph 2 | RegulatoryThis Phase 2 DPN study was terminated early (only 77 of a planned 200 patients enrolled) after the FDA placed a class-wide clinical hold on all anti-NGF antibody trials, including fulranumab, over rapidly-progressing-osteoarthritis (RPOA) safety signals. Trial status is TERMINATED (last updated 2016) with no DPN-specific successor trial found since. | source ↗ |
| Tanezumab | Pfizer | Nerve growth factor (NGF) | Diabetic Peripheral Neuropathic Pain | Ph 2 | SafetyPfizer and Eli Lilly discontinued tanezumab's entire global development program in October 2021 after an FDA Complete Response Letter and negative EU regulatory feedback, driven by rapidly-progressive-osteoarthritis safety concerns identified across the tanezumab program; the DPN-specific trial itself is recorded TERMINATED. | source ↗ |